Introduction
============

Multiple sclerosis (MS) is a chronic inflammatory autoimmune demyelinating disease of the central nervous system (CNS), affecting more than 2.3 million people in the world, with a predominance in women (female:male ratio 2:1, but some reports also indicated 3:1).[@b1-tcrm-14-1765]--[@b3-tcrm-14-1765] This disease is associated with different symptoms, depending on the location of the areas of demyelination in the CNS. The most frequent symptoms are as follows: fatigue, pain, bladder and bowel dysfunctions, visual problems, depression, spasticity, sexual dysfunctions, and movement and coordination problems.

Relapsing-remitting MS (RR-MS) is the most common MS form. About 85% of people have initially this form, characterized by symptomatic attacks (relapses) followed by partial or total recovery (remissions).[@b2-tcrm-14-1765] In most patients, the disease develops gradually into a chronic progressive phase, characterized by continuous accumulation of neurological impairments. Disease-modifying therapies (DMTs) are used with the purpose to prevent or reduce the number of relapses occurring in RR-MS and delay the progression of the disease.

DMTs include injectable drugs (interferon β-1a Avonex^®^ \[IFN β-1a-A\], interferon β-1a Rebif^®^ \[IFN β-1a-R\], interferon β-1b Betaferon^®^ \[IFN β-1b-B\], interferon β-1b Extavia^®^ \[IFN β-1b-E\], peginterferon β-1a \[PEG IFN β-1a\], and glatiramer acetate \[GA\]), intravenous therapies (natalizumab \[NAT\]), and oral agents (fingolimod \[FTY720\], teriflunomide, and dimethyl fumarate \[DMF\]).

All of these drugs showed immunomodulatory and anti-inflammatory properties, although using various mechanisms of action (MOAs). Interferons (IFNs) β exert their effect by promoting the anti-inflammatory cytokines, the inhibition of T-cell proliferation, and the reduction of inflammatory cell migration across the blood--brain barrier (BBB).[@b4-tcrm-14-1765]

The monoclonal antibody NAT inhibits leukocyte migration into the CNS, attenuating inflammation.[@b5-tcrm-14-1765]

GA is composed of synthetic peptides that simulate sequences of myelin, preventing the attack by immune system against this protein.[@b6-tcrm-14-1765]

Teriflunomide reduces the proliferation of T and B cells.[@b7-tcrm-14-1765] Similarly, FTY720 is also able to reduce the number of circulating lymphocytes and to inhibit their migration into the CNS.[@b8-tcrm-14-1765] DMF protects neuronal cells reducing oxidative stress and activating Nrf2.[@b9-tcrm-14-1765] The characteristics and MOAs of each drug are summarized in [Table 1](#t1-tcrm-14-1765){ref-type="table"}.

Based on their marketing authorization and their individual risk--benefit profile, MS drugs can be categorized into first- and second-line treatments. IFNs β and GA, as well as DMF and teriflunomide, are adopted as first-line therapies. In case of unsatisfactory response or safety issues with these drugs, the treatment can turn to second-line therapies, such as NAT and FTY720.[@b10-tcrm-14-1765] This distinction does not coincide perfectly in different countries. For example, FTY720 is approved as a first-line treatment in the United States, while it is labeled as a second-line drug in the European Union.[@b11-tcrm-14-1765]

The efficacy and the safety profile of these therapies vary from a moderate efficacy and high safety of first-line drugs to a higher efficacy closely associated with an increased safety risk of second-line treatments. In a previous study, both oral and injectable DMTs were reported to be well tolerated.[@b12-tcrm-14-1765] Among the oral agents, FTY720 presents more safety issues, requiring the monitoring of infections, cancers, lymphocyte, and levels of liver enzymes.[@b13-tcrm-14-1765]

In this scenario, pharmacovigilance becomes a fundamental source for the acquisition of new data, in order to deepen and constantly update the drug safety profile. Indeed, safety problems of some therapies only became evident during extension and postmarketing studies. This means that a more precise benefit--risk ratio is possible when a postmarketing surveillance is performed.

This postmarketing observational study shows the results of a multicentric pharmacovigilance program, sponsored by the Italian Drug Agency (AIFA). The aim of this study was to analyze expected and unexpected adverse drug reactions in RR-MS patients treated with DMTs, in order to evaluate their safety profile.

Patients and methods
====================

We performed a multicentric study involving three Italian regions (Liguria, Sicily, and Sardinia) for a duration of 24 months. Specifically, we collected adverse drug reaction reports from RR-MS patients belonging to four hospitals, of which two hospitals are located in Cagliari, one hospital is located in Messina, and one hospital is located in Genoa.

We monitored the following drugs: IFN β-1a-A, IFN β-1a-R, IFN β-1b-B, IFN β-1b-E, PEG IFN β-1a, GA, NAT, FTY720, teriflunomide, and DMF.

For each patient reporting adverse drug reactions, we collected personal data (age and sex) and medical history. Specifically, we recorded the presence of any comorbidities, previous MS therapies, and the number of doses taken before the adverse reaction onset.

All the reports received during our study were analyzed in order to evaluate the expected and unexpected adverse reactions occurred. In particular, an adverse drug reaction refers to an injury caused by taking a drug and we considered as expected any adverse effect already listed on the summary of product characteristics available on European Medicines Agency (EMA) and AIFA websites.[@b14-tcrm-14-1765]--[@b23-tcrm-14-1765] On the contrary, we assessed an event as unexpected if it was not consistent with the drug product information.

Finally, all the adverse reactions were classified in relation to the degree of intensity. We decided to consider "severe" any serious interference with the daily activity performance that required medical intervention/therapy and may need hospitalization; "moderate" any mild or moderate interference with the daily activity performance that could need a minimal medical intervention/therapy; and "mild" each event causing no interference with the daily activity performance and requiring no medical intervention/therapy.

Approval for this study is not required because it was authorized by AIFA and supported by funds from the pharmacovigilance multiregional project. Nevertheless, the privacy of all patients was guaranteed.

Statistical analysis
--------------------

Statistical analysis of the data was performed using the GraphPad Prism Version 6.0 program (GraphPad Software, Inc., La Jolla, CA, USA). Statistical significance was measured by chi-squared test. *P*-value \<0.05 was considered statistically significant.

Results
=======

The cohort examined in the four hospitals participating in this study was composed of 6,039 RR-MS patients. We received 265 adverse drug reaction reports from RR-MS patients (205 women and 60 men; average age 42.06±10.33 years). The distribution of RR-MS patients reporting adverse reactions in relation to age and sex is reported in [Figures 1](#f1-tcrm-14-1765){ref-type="fig"} and [2](#f2-tcrm-14-1765){ref-type="fig"}. Many subjects reported more than one adverse event, and for this reason, we have collected 411 reactions. Among these, 346 reactions have already been associated with the monitored drugs ([Table 2](#t2-tcrm-14-1765){ref-type="table"} and [Figure 3](#f3-tcrm-14-1765){ref-type="fig"}), while 65 reactions were unexpected ([Table 3](#t3-tcrm-14-1765){ref-type="table"} and [Figure 3](#f3-tcrm-14-1765){ref-type="fig"}). We observed that the choice to discontinue the therapy was mainly driven by the adverse reaction severity, even when the treatment was effective in improving the patient condition.

Some of the patients had received previously other therapies, as indicated in [Tables 2](#t2-tcrm-14-1765){ref-type="table"} and [3](#t3-tcrm-14-1765){ref-type="table"}. We can underline that the previous therapies included IFNs in most cases. On the contrary, almost all patients of our cohort treated with IFNs did not receive previous therapies, except for PEG IFN β-1a, in line with the fact that IFNs represent first-line treatment. Looking at the different therapies used, we can observe that the patients treated with three or more drugs showed mostly adverse events of moderate intensity. However, it was not possible to evaluate the influence of the sequence of different administered drugs on the appearance of the adverse reactions, because we had a small cohort of patients and dividing them on the bases of the sequence of drugs used caused a further fragmentation of patients in little groups, making difficult to reach a significant and valid result.

IFNs
----

In our study, about 42% of adverse drug reaction reports were attributed to IFNs. Specifically, we collected 154 adverse effects, among which only about 9% were unexpected. In relation to the severity degree, 5.84% were recorded as severe events.

IFN β-1a
--------

We received 23 reports of IFN β-1a-A, involving patients in 30.43% of cases suffered from comorbidities. For the 23 reports received, 21 reported only expected adverse events ([Table 2](#t2-tcrm-14-1765){ref-type="table"}), one reported only unexpected reactions ([Table 3](#t3-tcrm-14-1765){ref-type="table"}), while the other one showed both expected and unexpected events ([Tables 2](#t2-tcrm-14-1765){ref-type="table"} and [3](#t3-tcrm-14-1765){ref-type="table"}). We recorded 30 adverse effects related to IFN β-1a-A (1.3 adverse drug reactions per report, [Figure 3](#f3-tcrm-14-1765){ref-type="fig"}), of which two were unexpected ([Figures 4](#f4-tcrm-14-1765){ref-type="fig"} and [5](#f5-tcrm-14-1765){ref-type="fig"}). Specifically, these reactions were a moderate irritable mood and a severe erectile dysfunction ([Table 3](#t3-tcrm-14-1765){ref-type="table"}).

In regard of expected adverse events, for IFN β-1a-A, the value was significantly higher compared to the expected adverse events with NAT and FTY720. In particular, we received a significantly lower number of expected adverse events of moderate grade compared to IFN β-1a-R, IFN β-1b-B, PEG IFN β-1a, GA, FTY720, teriflunomide, and DMF. On the contrary, the number of those of mild grade was significantly higher compared to the mild adverse events recorded for IFN β-1a-R, IFN β-1b-B, GA, FTY720, and teriflunomide ([Figure 4](#f4-tcrm-14-1765){ref-type="fig"}).

Generally, the most common adverse effects during IFN β-1a-A therapy are flu-like symptoms and injection site reactions. Flu-like syndrome has also been frequently reported in our study (N=10) mainly of mild severity, and only in three cases, it was necessary to stop the drug administration. Injection site reactions were less common and recorded as a severe necrosis (N=1) leading to drug discontinuation and a moderate bruising (N=1).

General disorders induced by IFN β-1a-A were also collected, such as pyrexia (N=2), malaise (N=1), and pain (N=1), as well as musculoskeletal symptoms such as myalgia (N=2) and arthralgia (N=2). Other expected adverse events were as follows: vomiting (N=1), leukopenia (N=1), pruritus (N=1), diarrhea (N=1), tachycardia (N=1), mixed anxiety-depressive disorder (N=1), and hepatic transaminases increased (N=1). Finally, we recorded a severe nephrotic syndrome (N=1) reported by a 44-year-old female patient who had undergone 104 administrations before the reaction onset. This event is considered among the expected but rare adverse effect, and it resulted in the suspension of IFN β-1a-A.

From the reports received, it emerged that IFN β-1a-A was permanently discontinued in 34.78% of cases due to the adverse reactions, while in 4.35%, it was decided to suspend the treatment only temporarily. On the contrary, patients continued the drug administration in 60.87% of reports.

For IFN β-1a-R, we received 31 adverse drug reaction reports. Looking at expected adverse events, IFN β-1a-R showed a significantly higher number of reactions compared to NAT and FTY720. We observed only one expected adverse reaction of severe grade, showing a statistical significance compared to FTY720. The number of expected adverse reactions of moderate grade for IFN β-1a-R was significant compared to those for DMF and IFN β-1a-A. Those of mild grade were significantly higher compared to GA but lower compared to IFN β-1a-A ([Figure 4](#f4-tcrm-14-1765){ref-type="fig"}).

In 48.38% of cases, patients reporting adverse events ([Figure 1B](#f1-tcrm-14-1765){ref-type="fig"}) were affected by concomitant diseases ([Tables 2](#t2-tcrm-14-1765){ref-type="table"} and [3](#t3-tcrm-14-1765){ref-type="table"}).

We collected 36 adverse reactions related to IFN β-1a-R (1.2 adverse drug reactions per report), of which 32 adverse reactions were expected and four adverse reactions were unexpected ([Figure 3](#f3-tcrm-14-1765){ref-type="fig"}). The most common adverse effects observed were flu-like symptoms (N=8) and headache (N=7). Injection site reactions were signaled in 16.12% of reports. In particular, these effects were reported as abscess (N=1), pain (N=1), redness (N=1), erythema (N=1), and necrosis (N=1) of mild--moderate intensity.

IFN β-1a-R is frequently associated with hepatic dysfunction, but in our study, transaminases' elevation was reported a few times (N=3), as a moderate reaction never leads to drug discontinuation. General disorders were also observed, such as pyrexia (N=1) and asthenia (N=2), as well as musculoskeletal reactions of arthralgia (N=1), musculoskeletal stiffness (N=1), and pain in extremity (N=1). Moreover, we recorded mild insomnia (N=2) and severe urticaria (N=1).

Even a patient treated with IFN β-1a-R experienced an erectile dysfunction and following this adverse unexpected event, the drug was discontinued. The other recorded unexpected effects were all moderate and related to tachycardia (N=1), panic attacks (N=1), and nervousness (N=1).

Our evaluation showed that IFN β-1a-R was definitively discontinued in 35.48% of reports. The total number of unexpected adverse drug reactions for both IFN β-1a-A and IFN β-1a-R was significantly lower compared to NAT and FTY720 ([Figure 3](#f3-tcrm-14-1765){ref-type="fig"}).

IFN β-1b
--------

A total of 15 reports involving IFN β-1b-B were received in 24 months, 40% of which referred to subjects suffering from comorbidities ([Tables 2](#t2-tcrm-14-1765){ref-type="table"} and [3](#t3-tcrm-14-1765){ref-type="table"}).

We collected 21 adverse effects that were all expected (1.4 adverse drug reactions per report; [Figure 3](#f3-tcrm-14-1765){ref-type="fig"}), a significantly higher number compared with expected adverse reactions for IFN β-1b-E, NAT, and FTY720. The most common referred to injection site reactions, found in 60% of reports, and described as pain (N=5), mass (N=2), bruising (N=1), skin reaction (N=1), and abscess (N=1) of mild--moderate intensity. Additionally, \~33.3% of cases were related to general disorders, such as flu-like symptoms (N=1), pyrexia (N=2), asthenia (N=1), and malaise (N=1). Moreover, headache (N=2), myasthenia (N=1), paresthesia (N=1), lymphopenia (N=1), and γ-glutamyl-transferase increased (N=1) were also recorded. Looking at the severity, only one severe expected reaction was received, with a significant difference compared to FTY720. Moderate grade expected reactions were significantly higher compared to those for IFN β-1a-A, while the number of those of mild grade was significantly lower compared to the same drug ([Table 2](#t2-tcrm-14-1765){ref-type="table"}, [Figure 4](#f4-tcrm-14-1765){ref-type="fig"}).

Among the reports analyzed, 73.3% resolved to IFN β-1b-B discontinuation due to the adverse reaction onset.

IFN β-1b-E showed the lowest number of expected adverse events, and in particular only one of mild grade, a data statistically significant compared to GA. During our project, we received only two reports involving IFN β-1b-E. The first case was related to a subject with no concurrent disease who experienced a moderate abdominal pain and an unexpected moderate rachialgia, because of which the drug was discontinued. The other report involved a patient who suffered from depression and disk herniation as comorbidities and experienced an unexpected urticaria of mild severity not leading to drug discontinuation ([Tables 2](#t2-tcrm-14-1765){ref-type="table"} and [3](#t3-tcrm-14-1765){ref-type="table"}).

IFN β-1b-E showed a significant elevated number of unexpected adverse drug reactions compared to IFN β-1b-B ([Figure 3](#f3-tcrm-14-1765){ref-type="fig"}).

PEG IFN β-1a
------------

Among the different IFNs β, the highest number of reports we received was attributed to PEG IFN β-1a (N=42). The number of expected adverse events was significantly higher compared to those for NAT and FTY720. Regarding the severity grade, PEG IFN β-1a showed a significantly lower number of severe expected adverse events compared to those with GA and FTY720 but a significantly higher number of expected reactions of mild grade compared to the same therapies. The number of expected moderate reactions was significantly higher compared to IFN β-1a-A but lower compared to GA ([Figure 4](#f4-tcrm-14-1765){ref-type="fig"}).

Patients reporting adverse effects suffered from concomitant diseases in 38% of cases ([Tables 2](#t2-tcrm-14-1765){ref-type="table"} and [3](#t3-tcrm-14-1765){ref-type="table"}).

We collected 64 adverse reactions (1.5 adverse drug reactions per report, [Figure 3](#f3-tcrm-14-1765){ref-type="fig"}), of which 57 adverse reactions have previously been associated with PEG IFN β-1a ([Figures 3](#f3-tcrm-14-1765){ref-type="fig"} and [4](#f4-tcrm-14-1765){ref-type="fig"} and [Table 2](#t2-tcrm-14-1765){ref-type="table"}) and seven adverse reactions were unexpected ([Figures 3](#f3-tcrm-14-1765){ref-type="fig"} and [5](#f5-tcrm-14-1765){ref-type="fig"} and [Table 3](#t3-tcrm-14-1765){ref-type="table"}). Specifically, we noticed flu-like syndrome (N=17) in 40.47% of reports, with an intensity ranging from mild to severe. An equal percentage was related to mild--moderate injection site reactions, described as redness (N=9), rash (N=5), erythema (N=2), and necrosis (N=1). General disorders of pyrexia (N=6) and asthenia (N=2) also commonly occurred, as well as myalgia (N=4), arthralgia (N=3), urticaria (N=3), lymphopenia (N=3), and thrombocytopenia (N=1). Moreover, a moderate elevation of hepatic transaminases (N=1) was recorded.

All the reported unexpected reactions had a mild--moderate severity and referred to oral aphthae (N=1), eyelid edema (N=1), localized erythema (N=1), unmotivated anger (N=1), confusional state (N=1), diarrhea (N=1), and abdominal pain (N=1).

As a consequence of the adverse reaction onset, it was decided PEG IFN β-1a discontinuation in 26.83% of reports.

GA
--

A significantly higher number of expected adverse events were reported for GA compared to NAT and FTY720. The majority were of moderate grade. In particular, the number of moderate grade expected adverse reactions was significantly higher compared to those received with IFN β-1a-A, PEG IFN β-1a, and DMF. The number of mild reactions was significant compared to the received mild expected events for IFN β-1b-E and NAT and significantly lower compared to IFN β-1a-A, IFN β-1a-R, PEG IFN β-1a, teriflunomide, and DMF. The number of expected adverse reactions of severe grade for GA was significantly higher compared to PEG β-1a ([Figure 4](#f4-tcrm-14-1765){ref-type="fig"}).

We received 30 reports involving GA-treated patients who suffered from concurrent diseases in 46.6% of cases ([Tables 2](#t2-tcrm-14-1765){ref-type="table"} and [3](#t3-tcrm-14-1765){ref-type="table"}).

We counted an amount of 59 adverse reactions attributed to GA (two adverse drug reactions per report), 13.56% of which were unexpected ([Table 3](#t3-tcrm-14-1765){ref-type="table"} and [Figure 3](#f3-tcrm-14-1765){ref-type="fig"}). Particularly, \~33% of reports referred to reactions of moderate--severe grade, which occurred immediately after GA administration and mostly resolved within a day, such as rash (N=5), dyspnea (N=4), tachycardia (N=3), pyrexia (N=2), flushing (N=2), chest pain (N=2), choking sensation (N=2), anxiety (N=2), palpitation (N=1), syncope (N=1), vomiting (N=2), depression (N=1), nausea (N=1), confusional state (N=1), and visual field defect (N=1). Injection site reactions of mild--moderate severity were also common (30% of reports), and they manifested as mass (N=5), rash (N=3), pruritus (N=1), pain (N=1), and redness (N=1). In addition, moderate or severe hypersensitivity reactions (N=3) occurred after GA administration and, in all of these cases, the drug discontinuation was decided. The remaining expected events recorded were mixed anxiety-depressive disorder (N=1), influenza (N=2), urticaria (N=2), skin disorder of unspecified nature (N=1), and motor dysfunction (N=1).

The unexpected adverse reactions were significant compared to those received for NAT and FTY720. From our evaluation, we found that the unexpected events were mainly of moderate--severe degree and referred to panic attacks (N=3), tachypnea (N=1), and irritable mood (N=1). In addition, a patient reported vertigo and postural instability of moderate intensity, as well as a slight hemiparesis for \~5 months, which however did not result in drug discontinuation. Among the reports analyzed, 53.33% resulted in GA discontinuation due to the adverse reaction onset.

NAT
---

For NAT, we received a significantly lower number of expected adverse reactions compared to those recorded for IFN β-1a-A, IFN β-1a-R, IFN β-1b-B, PEG IFN β-1a, GA, teriflunomide, and DMF. In addition, the number of mild grade expected reactions was significant compared to those for GA ([Figure 4](#f4-tcrm-14-1765){ref-type="fig"}).

We received seven reports from NAT-treated patients who have undergone 3--109 administrations (one infusion/month) at the time of adverse reaction onset. In particular, only two reports belonged to subjects who suffered from concomitant diseases: the first one was affected by diabetes and the other one showed mixed anxiety-depressive disorder and conversion disorder.

About 86% of reports included patients who received NAT for \>24 months, a period after which the risk of developing progressive multifocal leukoencephalopathy (PML) increases. Nevertheless, no case of this infection was reported.

We collected 11 adverse drug reactions, mainly of mild--moderate severity (1.6 adverse drug reactions per report), 63.64% of which were unexpected ([Figures 3](#f3-tcrm-14-1765){ref-type="fig"} and [5](#f5-tcrm-14-1765){ref-type="fig"} and [Table 3](#t3-tcrm-14-1765){ref-type="table"}). Specifically, we highlighted pyrexia (N=3) and chest pain (N=1) as expected reactions. Furthermore, we recorded unexpected events described as cough (N=2), femoral fracture (N=1), paresthesia (N=1), hyposthenia (N=1), diarrhea (N=1), and bronchopneumonia (N=1). The number of unexpected drug reactions was significantly higher compared to IFN β-1a-A, IFN β-1a-R, and IFN β-1b-B. A significant difference was also recorded compared to GA and DMF. In particular, the mild ones were higher compared to FTY720 ([Figure 5](#f5-tcrm-14-1765){ref-type="fig"}).

Finally, our analysis underlined that only two of the seven cases received have discontinued NAT following the adverse reaction onset.

Fingolimod
----------

For FTY720, we received a significantly lower number of expected adverse reactions compared to IFN β-1a-A, IFN β-1a-R, IFN β-1b-B, PEG IFN β-1a, GA, teriflunomide, and DMF. In particular, the number of those of severe grade was significant compared to DMF, and it was significantly higher compared to those of teriflunomide, IFN β-1a-R, IFN β-1b-B, and PEG IFN β-1a. The reactions of moderate grade were significantly higher compared to IFN β-1a-A. On the contrary, the reactions of mild grade were significantly lower compared to IFN β-1a-A, PEG IFN β-1a, and DMF ([Figure 4](#f4-tcrm-14-1765){ref-type="fig"}).

We received 19 reports involving FTY720-treated patients. A total of 57.89% of cases suffered from concomitant diseases ([Tables 2](#t2-tcrm-14-1765){ref-type="table"} and [3](#t3-tcrm-14-1765){ref-type="table"}).

We collected an amount of 31 adverse drug reactions attributed to FTY720 (1.6 adverse drug reactions per report), 45.16% of which were unexpected ([Table 3](#t3-tcrm-14-1765){ref-type="table"} and [Figure 3](#f3-tcrm-14-1765){ref-type="fig"}).

During FTY720 treatment, the elevation of hepatic enzymes is common and often causes drug discontinuation. In our study, increase in liver transaminases was also recorded (N=4), for which the temporary suspension of therapy was decided until these values have returned to the normal range.

The immunosuppressive effects of FTY720 may increase the risk of infections too, especially in reference to opportunistic ones. In our analysis, the reported infections were candidiasis (N=1), influenza (N=1), and urinary tract infection (N=1). Moreover, it is well known that FTY720 commonly reduces the number of circulating lymphocytes due to its MOA, but in our study, only one patient reported a moderate lymphopenia without leading to FTY720 discontinuation. However, other reactions related to the blood and lymphatic system have been observed, represented by leukopenia (N=1) and peripheral edema (N=1).

In clinical trials and in real-world practice, basal-cell carcinoma has been observed in FTY720-treated patients; for this reason, vigilance for skin lesions is strongly recommended. In our study, a case of this skin cancer was reported by a 48-year-old female patient treated with FTY720 for 15 months. This event was classified as moderate and led to drug discontinuation.

Finally, the remaining expected reactions recorded were headache (N=3), asthenia (N=1), alopecia (N=1), and pruritus (N=1).

The reported unexpected effects were mainly of moderate--severe intensity. The number of unexpected drug reactions was significant compared to IFN β-1a-A, IFN β-1a-R, IFN β-1b-B, PEG IFN β-1a, GA, teriflunomide and DMF ([Figure 3](#f3-tcrm-14-1765){ref-type="fig"}). In particular, we observed psychiatric disorders, such as insomnia (N=2), behavioral disorder (N=1), and anxiety (N=1), as well as musculoskeletal adverse reactions given by pain in extremity (N=2), muscle spasms (N=1), and arthralgia (N=1). Isolated cases of warts (N=1), acne worsening (N=1), hypothyroidism (N=1), and chest pain (N=1) were also reported. In addition, a severe bilateral ovarian carcinoma and an aortic dissection, which led the patient to death, were noticed.

In 35.29% of reports, it was necessary to stop FTY720 administration permanently, while it was decided only a temporary suspension in 17.65% of reports. On the contrary, 47.06% of reports described the drug continuation even after the adverse reaction onset.

Teriflunomide
-------------

The number of expected adverse reactions was significantly higher compared to those for NAT and FTY720. The number of those of severe grade was significantly lower compared to FTY720. Reactions of moderate grade were significantly higher compared to IFN β-1a-A. The expected reactions of mild grade were higher compared to GA but lower compared to IFN β-1a-A ([Figure 4](#f4-tcrm-14-1765){ref-type="fig"}). We received 38 reports involving teriflunomide-treated patients, 52.63% of which suffered from comorbidities ([Tables 2](#t2-tcrm-14-1765){ref-type="table"} and [3](#t3-tcrm-14-1765){ref-type="table"}).

Our analysis led to the registration of 61 adverse reactions (1.6 adverse drug reactions per report), 11.48% of which were unexpected ([Table 3](#t3-tcrm-14-1765){ref-type="table"}).

As already well known from the information available on this drug, gastrointestinal disorders are the most frequent adverse reactions reported by the majority of patients receiving teriflunomide. In our study, such events were recorded in 42.10% of reports and all of them had a mild--moderate severity grade. In particular, these subjects experienced diarrhea (N=8), abdominal pain upper (N=5), nausea (N=3), gastroenteritis (N=3), and pancreatitis (N=2).

Generally, teriflunomide has also been associated with the elevation of blood pressure and a decrease in leukocytes, as well as an increase in hepatic enzymes. For this reason, special precautions must be performed before and after teriflunomide treatment, which consist of assessing and monitoring of the following parameters: blood pressure, blood cells' count, and hepatic function. In our analysis, we also observed hypertension (N=7), hepatic transaminases increased (N=4), leukopenia (N=1), and neutropenia (N=1). Alopecia (N=9) was another effect commonly reported in our project, and it was described mainly as a mild--moderate event. The remaining expected reactions recorded were headache (N=2), weight decrease (N=1), musculoskeletal pain (N=2), arthralgia (N=1), asthenia (N=1), pain (N=2), respiratory tract infection (N=1), and rash (N=1).

Finally, we noticed depression (N=1), chest pain (N=1), herpes zoster (N=1), tachycardia (N=2), and pruritus (N=1) as unexpected events, with an intensity grade ranging from moderate to severe. Strangely, a severe case of PML was also found, an infection that has not been associated with teriflunomide administration yet. No mild grade events were received.

In 39.47% of reports we received, it was decided definitively to discontinue teriflunomide; in 7.9%, the treatment was interrupted temporarily, whereas 52.63% described the continuation of this drug despite the adverse reaction onset.

DMF
---

For DMF, we received the highest number of expected adverse reactions, with a significant difference compared to NAT and FTY720. The number of those of severe grade was significant compared to FTY720. The moderate grade expected adverse reactions reached a statistical significance compared to IFN β-1a-A, IFN β-1a-R and GA. The mild adverse reactions were higher compared to GA and FTY720 ([Figure 4](#f4-tcrm-14-1765){ref-type="fig"}). We received 58 reports attributed to DMF, involving patients who were affected by comorbidities in 37.93% of cases ([Tables 2](#t2-tcrm-14-1765){ref-type="table"} and [3](#t3-tcrm-14-1765){ref-type="table"}). We collected a total of 95 adverse effects (1.6 adverse drug reactions per report), of which 84.21% have already been associated with DMF ([Figures 3](#f3-tcrm-14-1765){ref-type="fig"} and [4](#f4-tcrm-14-1765){ref-type="fig"} and [Table 2](#t2-tcrm-14-1765){ref-type="table"}) and 15.79% were unexpected ([Figures 3](#f3-tcrm-14-1765){ref-type="fig"} and [5](#f5-tcrm-14-1765){ref-type="fig"} and [Table 3](#t3-tcrm-14-1765){ref-type="table"}).

Generally, a well-known manifestation during DMF treatment is flushing, which was also registered in our study in \~56.89% of reports (N=33), with a mild or moderate severity. Gastrointestinal adverse reactions also commonly occurred in 43.10% of cases and reported as diarrhea (N=6), abdominal pain and abdominal pain upper (N=12), nausea (N=2), gastrointestinal disorders (N=8), and gastroenteritis (N=1). Several cases of rash (N=4), pruritus (N=6), and lymphopenia (N=3) were recorded too. In addition, a few patients experienced hepatic disorders during DMF treatment, related to elevation of transaminases (N=2) and a severe drug-induced liver injury (N=1). The remaining expected effects reported were asthenia (N=1) and burning sensation on a patient trunk (N=1).

The number of unexpected adverse events was significant compared to those recorded for NAT and FTY720 ([Figure 3](#f3-tcrm-14-1765){ref-type="fig"}).

The unexpected effects we noticed referred to thrombocytosis (N=1), lymphadenopathy (N=1), respiratory failure (N=1), rhinitis (N=1), dyspnea (N=1), headache (N=2), vertigo (N=2), insomnia (N=1), pain (N=1), vaginal discharge (N=1), weight decrease (N=1), and chest pain (N=1). In addition, we recorded omphalitis (N=1), an infection of the umbilical stump.

Finally, our analysis showed that DMF was permanently discontinued in 36.21% of reports due to the adverse reactions, whereas in 3.45%, it was decided to suspend the treatment only temporarily; 60.34% reported the continuation of DMF administration.

Comparison of adverse drug reactions occurred in DMTs with different routes of administration
---------------------------------------------------------------------------------------------

DMTs may be administered through different routes. In particular, IFN β-1a-R, IFN β-1b, PEG IFN β-1a, and GA are injected subcutaneously; IFN β-1a-A is administered by intramuscular injection, while NAT is an intravenous infusion therapy. FTY720, teriflunomide, and DMF are oral agents.

We compared drugs administered through injection/infusion with those given orally.

For these two groups, we put together the collected data to perform a comparative analysis. Starting from 265 reports related to DMTs treated patients, we analyzed an amount of 411 adverse drug reactions, of which 224 adverse drug reactions were attributed to injectable/intravenous agents and 187 adverse drug reactions were recorded during oral drugs, corresponding to 54.5 and 45.5%, respectively. Specifically, we collected 195 expected (16 severe, 116 moderate, 62 mild, and one unavailable intensity) and 29 unexpected adverse reactions (three severe, 16 moderate, nine mild, and one unavailable intensity) related to injectable or infusion therapies. The percentages of expected and unexpected events were 87.05 and 12.95, respectively. In addition, 151 expected (15 severe, 82 moderate, and 54 mild) and 36 unexpected (10 severe, 23 moderate, and three mild) adverse effects were reported during oral therapies. A total of 80.75% of the reactions recorded in oral agents have already been associated with these drugs, whereas 19.25% were unexpected.

Discussion
==========

MS is a chronic disease of the CNS primarily characterized by demyelination and axonal loss caused by autoreactive T cells. Although its etiology has not been completely understood yet, over the last 20 years, numerous therapies have been made available to patients in order to improve their quality of life. Just for this purpose, the expansion of treatment options for MS has led to the introduction of DMTs with the aim of improving the clinical course of this disease and reducing long-term disability.

The first consideration that we can deduce from this study is that only a small portion of RR-MS patients show the onset of adverse events during the therapeutic treatment. Indeed, only 265 patients on a total of 6,039 showed at least one adverse drug reaction.

We observed that in most cases, IFNs were administered as first therapy. Furthermore, in the majority of patients treated with previous treatments, the first drugs administered were IFNs. However, it was not possible to properly consider the importance of the sequence of the drugs used on the onset of adverse events, because of the wide variety of the different combinations of therapies used and the small cohort of this study that caused an excessive fragmentation in small groups of patients.

During our program, we monitored five different IFNs. The whole group has been involved in a high number of adverse drug reactions that were almost completely expected and of mild-to-moderate intensity. Very few events were unexpected, and among these, only one was of a severe grade. The latter referred to a case of erectile dysfunction in a 53-year-old male patient, who had undergone 308 IFN β-1a-A administrations before the adverse reaction onset.

These data led us to confirm the safety profile of these drugs, similar to what Zettl et al[@b24-tcrm-14-1765] affirmed in their review, in which they have defined the IFNs related adverse reactions as mild, manageable, and reversible.

The highest amount of reported adverse effects was attributed to PEG IFN β-1a and IFN β-1a-R. On the contrary, IFN β-1b-E collected the lowest number of adverse events among those attributed to IFNs during our program. It is important to evaluate when the adverse reaction appeared during the course of therapy, given that adverse events appearing later could be due to accumulated toxicity. Interestingly, in most cases, all IFNs, except PEG IFN β-1a, caused adverse reactions after the administration of an elevated number of doses. On the contrary, PEG IFN β-1a-associated adverse events appeared earlier.

GA showed a comparable trend to PEG IFN β-1a: for both drugs, an analog number of reported adverse reactions and a similar severity in unexpected events were recorded; on the contrary, expected reaction intensity tended to be more moderate--severe in GA-treated patients.

For IFNs and GA, injection site reactions were the most common. In particular, we highlighted pain, redness, pruritus, mass, and skin manifestations for both of these drugs, while IFNs were also related to abscess, necrosis, and bruising. Furthermore, only IFNs have been strongly associated with flu-like symptoms. These data are in agreement with Moses and Brandes,[@b25-tcrm-14-1765] who obtained similar information after performing a search on the MEDLINE and EMBASE databases to analyze the studies published between 1985 and 2007.

NAT was one of the drugs with the lowest number of reported adverse reactions, despite being a strongly monitored agent due to the drug--PML risk correlation. PML is a demyelinating brain disease caused by John Cunningham virus (JCV) infection that occurs in immunocompromised patients but also associated with specific immunotherapies. As of December 7, 2017, there have been 756 confirmed cases of NAT-associated PML.[@b26-tcrm-14-1765] In the STRATA MS study, 14 confirmed cases of PML were detected on a total of 1,094 patients. All these patients had detectable anti-JCV antibodies at least 6 months before diagnosis and after at least 2 years of NAT exposure.[@b27-tcrm-14-1765] However, no report of such infection correlated with this drug was detected in our program, but it is important to notice that it may be due to the low number of reports received for NAT.

Among the recorded NAT-related adverse reactions, we observed more unexpected than expected events; however, almost all had a mild-to-moderate intensity and they did not result in NAT discontinuation. Our results are in line with another pharmacovigilance program on NAT conducted in Sicily region, which showed a similar severity grade in the reactions they analyzed.[@b28-tcrm-14-1765]

For years, only the DMTs requiring parenteral administration had been available. More recently, a great goal has been achieved in the MS therapeutic scenario thanks to the introduction of oral DMTs, which should ensure a higher adherence due to their easier route of administration. In this context, pharmacovigilance is essential for monitoring the safety profile of these agents and detecting any adverse reactions not shown in clinical trials.

Considering oral DMTs, DMF recorded the highest number of adverse events, both for expected and for unexpected effects. The expected reactions were mostly of mild--moderate intensity, while among the unexpected moderate severity prevailed. Teriflunomide was the second for the number of reported reactions, in which moderate expected events dominated. However, unexpected effects were the lowest compared to the other oral therapies, but none of them was mild.

Finally, FTY720 was the oral agent reporting the lowest number of adverse events, but it recorded the highest level of severe unexpected reactions in the entire sample of the examined drugs.

Both teriflunomide and DMF have been commonly associated with gastrointestinal disorders, described mainly as diarrhea, abdominal pain, nausea, and gastroenteritis. Together with these adverse effects, the most frequent event associated with DMF was flushing, while alopecia and hypertension have been reported by several teriflunomide-treated patients. All this information is in accordance with data from TEMSO and DEFINE studies, two Phase III clinical trials describing an increased incidence of the reactions mentioned earlier in patients receiving the active treatment compared to the placebo group.[@b29-tcrm-14-1765],[@b30-tcrm-14-1765]

A common point highlighted during our analysis in all the oral DMTs was an increase in liver enzymes, an event already described in Phase III clinical trials. In particular, elevations in hepatic enzyme levels were common findings in TEMSO and FREEDOMS studies, with a percentage of 14.2 and 15.8, respectively.[@b8-tcrm-14-1765],[@b29-tcrm-14-1765] This adverse reaction was also associated with DMF in DEFINE trial, but with a lower percentage (6%).[@b30-tcrm-14-1765] Also, in our study, among patients reporting oral DMTs related adverse reactions, a higher percentage was associated with FTY720 (21%) and teriflunomide (10.5%), while a lower number of cases was reported for DMF (3.4%).

In order to verify if the recorded unexpected reactions had already been highlighted, we evaluated them compared to what is reported in literature.

One FTY720-treated patient died because of an aortic dissection. The subject in question was a 65-year-old man treated with FTY720 for more than a year and without concomitant disease related to the cause of death. No other cases of aortic dissection during FTY720 therapy had previously been described in the literature. Anyhow, this agent has already been associated with cardiovascular events, such as hypertension, T-wave inversion, bradycardia, bradyarrhythmia, myocardial ischemia, and atrioventricular block.[@b21-tcrm-14-1765],[@b31-tcrm-14-1765]

Another unexpected adverse event reported in our study was a bilateral ovarian carcinoma, occurred in a 50-year-old female patient treated with FTY720 for 5 years. From information available in the summary of product characteristics and literature, it is known that this drug has been involved in several cases of cancer, such as Merkel cell carcinoma, Kaposi sarcoma, melanoma, and basal cell carcinoma.[@b31-tcrm-14-1765]--[@b34-tcrm-14-1765] Even in our study, this last skin cancer has been reported in a 48-year-old female patient treated with FTY720 for 15 months.

At the same time, a potential anticancer role of FTY720 has already been shown, due to inhibition of the proto-oncogene sphingosine kinase 1 (SK1).[@b35-tcrm-14-1765] In vitro and in vivo studies demonstrate the ability of this agent to induce apoptosis and autophagy in ovarian cancer cells and decrease tumor weight, supporting its potential therapeutic role in this type of cancer.[@b36-tcrm-14-1765],[@b37-tcrm-14-1765] This evidence is in contrast with our case report of bilateral ovarian carcinoma, questioning the correlation between this drug and the adverse event occurred.

In our study, FTY720 has also been correlated to hypothyroidism. This unexpected event occurred in a 32-year-old woman treated with the drug in question for \>2 months. Patients affected by MS show an important risk of autoimmune diseases, such as thyroid dysfunctions;[@b38-tcrm-14-1765] FTY720 may increase this susceptibility due to its immunomodulatory MOA. Another similar case was previously described in the literature, strengthening this possible association and the need of additional researches.[@b39-tcrm-14-1765]

Strangely, a case involving a 36-year-old woman who contracted PML during teriflunomide treatment was reported.[@b40-tcrm-14-1765] After a 10-year therapy with IFN β-1a, the patient has undergone NAT for \~3 years (33 infusions). This last agent was discontinued because of a JCV index of 3.6, although the last magnetic resonance imaging (MRI) performed after NAT suspension showed no signs of PML.[@b40-tcrm-14-1765] Subsequently, the patient started teriflunomide treatment. After 8 months from NAT discontinuation, the teriflunomide-treated patient underwent a brain MRI, which detected a new lesion highly suggestive of PML. Actually, the occurrence of this infection after only 3 months of teriflunomide administration suggests a long incubation of JCV and the possible involvement of NAT.[@b40-tcrm-14-1765]

Previously, some PML cases associated with the oral DMF and FTY720 have been described.[@b41-tcrm-14-1765] On the contrary, no certain teriflunomide-related PML has been reported yet, although some cases involving its precursor molecule leflunomide were observed.[@b42-tcrm-14-1765],[@b43-tcrm-14-1765] These results suggest the importance of a more prolonged PML monitoring and the need for increased data related to DMTs--PML correlation.

Considering NAT, an adverse drug reaction case report of bronchopneumonia in a 53-year-old female patient was received. This subject had undergone 34 NAT administrations before the adverse reaction onset. Although this event is unexpected according to the summary of product characteristics, different cases of pulmonary infection during NAT treatment have been described in the literature, such as pulmonary tuberculosis, *Mycobacterium intracellulare* pneumonia, and a case of *Mycobacterium kansasii* lung infection.[@b44-tcrm-14-1765]--[@b46-tcrm-14-1765] This evidence suggests a possible role of this agent in opportunistic pulmonary infections, probably due to its immunosuppressive action.

In our study, we analyzed a case of omphalitis in a 24-year-old male patient treated with DMF for 5 months.[@b47-tcrm-14-1765] Omphalitis is an infection of the umbilical stump that mainly affects newborns and only rarely adults. No case of omphalitis during DMF treatment has been reported in the literature yet. However, the recovery of the infection after DMF discontinuation and the reappearance of the event following the restart of this agent suggest a connection between the treatment and the development of omphalitis.

Two cases of headache occurring during DMF therapy were also reported. The patients in question were a 37-year-old woman and a 27-year-old man treated with this drug for 3 months and 1 month, respectively. We considered these events as unexpected because headache is not mentioned in the summary of product characteristics.[@b23-tcrm-14-1765] However, a multi-centric study in RR-MS patients has reported it as a common adverse reaction in their cohort during DMF treatment, with a dose-related pattern.[@b48-tcrm-14-1765]

Finally, we received a report involving a 54-year-old woman in therapy with DMF from 1 month who showed widespread pain and asthenia. The patient presented fibromyalgia as concomitant disease. Pain is not an expected effect of this agent; however, musculoskeletal pain and articular pain occurring during DMF therapy have recently been described.[@b49-tcrm-14-1765] Despite this new evidence, we cannot exclude fibromyalgia among the causes of this adverse event.

By examining the route of administration of DMTs and comparing the data collected for injectable/intravenous drugs and oral agents, we observed that the trend in these two groups was rather similar, even if a higher percentage of unexpected events were detected during oral therapies, especially in reference to those of a severe intensity. These data reflect an important knowledge deficit in the long-term safety of oral DMTs, which have been approved in our country only a few years ago, starting in 2011 with FTY720.

Conclusion
==========

In our study, we observed that these treatments seem safe, given that only a small portion of RR-MS patients developed adverse drug events. Furthermore, the most frequently reported adverse reactions occurred during DMTs were expected. However, the higher number of unexpected events and the magnitude of some serious effects reported for oral therapies reflect the lack of data for these treatments that were introduced later in the clinical practice and the importance of postmarketing safety studies to improve knowledge on the subject. Another additional explanation to justify the higher number of unexpected reactions for oral drugs could be the greater attention of health professionals toward these treatments that are still little known compared to the others. Both teriflunomide and FTY720 are in fact under additional monitoring, according to EMA directive.

The limitation of this study was the small number of centers participating, but it encourages and underlines the importance of pharmacovigilance studies, in order to protect the health of patients who already presented a disease of such importance and to better characterize the long-term safety profile of MS therapies.
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![(**A**--**D**) Distribution of RR-MS population reporting adverse reactions treated with interferons, in relation to age and sex.\
**Abbreviations:** F, female; IFN β-1a-A, interferon β-1a Avonex^®^; IFN β-1a-R, interferon β-1a Rebif^®^; IFN β-1b-B, interferon β-1b Betaferon^®^; M, male; RR-MS, relapsing-remitting multiple sclerosis.](tcrm-14-1765Fig1){#f1-tcrm-14-1765}

![(**A**--**E**) Distribution of RR-MS population reporting adverse reactions in relation to age and sex.\
**Abbreviations:** F, female; M, male; RR-MS, relapsing-remitting multiple sclerosis.](tcrm-14-1765Fig2){#f2-tcrm-14-1765}

![Total expected and unexpected adverse events for each drug evaluated.\
**Notes:** \*\**P*\<0.01. \*\*\**P*\<0.001. \*\*\*\**P*\<0.0001.\
**Abbreviations:** DMF, dimethyl fumarate; FTY720, fingolimod; GA, glatiramer acetate; IFN β-1a-A, interferon β-1a Avonex^®^; IFN β-1a-R, interferon β-1a Rebif^®^; IFN β-1b-B, interferon β-1b Betaferon^®^; IFN β-1b-E, interferon β-1b Extavia^®^; NAT, natalizumab; PEG IFN β-1a, peginterferon β-1a.](tcrm-14-1765Fig3){#f3-tcrm-14-1765}

![(**A**--**C**) Expected adverse events divided on the bases of the severity grade.\
**Notes:** \**P*\<0.05. \*\**P*\<0.01. \*\*\**P*\<0.001. \*\*\*\**P*\<0.0001.\
**Abbreviations:** DMF, dimethyl fumarate; FTY720, fingolimod; GA, glatiramer acetate; IFN β-1a-A, interferon β-1a Avonex^®^; IFN β-1a-R, interferon β-1a Rebif^®^; IFN β-1b-B, interferon β-1b Betaferon^®^; IFN β-1b-E, interferon β-1b Extavia^®^; NAT, natalizumab; PEG IFN β-1a, peginterferon β-1a.](tcrm-14-1765Fig4){#f4-tcrm-14-1765}

![(**A**--**C**) Unexpected adverse events divided on the bases of the severity grade.\
**Note:** \**P*\<0.05.\
**Abbreviations:** DMF, dimethyl fumarate; FTY720, fingolimod; GA, glatiramer acetate; IFN β-1a-A, interferon β-1a Avonex^®^; IFN β-1a-R, interferon β-1a Rebif^®^; IFN β-1b-B, interferon β-1b Betaferon^®^; IFN β-1b-E, interferon β-1b Extavia^®^; NAT, natalizumab; PEG IFN β-1a, peginterferon β-1a.](tcrm-14-1765Fig5){#f5-tcrm-14-1765}

###### 

Details about the drugs considered in this study

  Drug                    Commercial name and manufacturer                                                    Characteristics and mechanism of action                                                                                                                                                                                                                                                                                                                                                                                                                                                                   References
  ----------------------- ----------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------
  IFN β-1a-A              Avonex^®^; Biogen, Cambridge, MA, USA                                               Avonex is glycosylated like natural IFN β and exerts its biological actions through the binding to specific receptors on cell surface that starts a cascade of intracellular events leading to the expression of numerous genes and markers, such as MHC Class I, Mx protein, 2″/5′-oligoadenylate synthetase, β2-microglobulin, and neopterin                                                                                                                                                            [@b14-tcrm-14-1765]
  IFN β-1a-R              Rebif^®^; Merck Serono, Darmstadt, Germany                                          Rebif presents the same amino acid sequence of endogenous human IFN β. It is produced in mammalian cells (Chinese hamster ovary) and is glycosylated such as the natural protein                                                                                                                                                                                                                                                                                                                          [@b15-tcrm-14-1765]
  IFN β-1b-B IFN β-1b-E   Betaferon^®^; Bayer, Leverkusen, Germany Extavia^®^; Novartis, Basel, Switzerland   The biological actions of IFN β-1b are mediated by its binding to specific receptors on the cell surface that triggers the expression of gene products that mediates its biological actions. IFN β-1b both decreases the binding affinity and enhances the internalization and degradation of the IFN γ receptor. IFN β-1b also enhances the suppressor activity of peripheral blood mononuclear cells                                                                                                    [@b16-tcrm-14-1765], [@b17-tcrm-14-1765]
  PEG IFN β-1a            Plegridy^®^; Biogen, Cambridge, MA, USA                                             Plegridy is an IFN β-1a conjugated with a single, linear molecule of methoxy poly(ethyleneglycol)-*O*-2-methylpropionaldehyde. It binds to the type I IFN receptor on the cell surface inducing a cascade of intracellular events leading to the regulation of IFN-responsive gene expression. Biological effects may include upregulation of anti-inflammatory cytokines, downregulation of pro-inflammatory cytokines, and inhibition of activated T cells' migration across the blood--brain barrier   [@b18-tcrm-14-1765]
  GA                      Copaxone^®^; Teva Pharmaceutical Industries, Petach Tikva, Israel                   GA is a pool of synthetic peptides that simulate sequences of myelin and then acts as a false target preventing the immune system attack against this protein                                                                                                                                                                                                                                                                                                                                             [@b6-tcrm-14-1765], [@b19-tcrm-14-1765]
  NAT                     Tysabri^®^; Biogen, Cambridge, MA, USA                                              NAT is a recombinant humanized anti-α4-integrin antibody produced in a murine cell line by recombinant DNA technology. Its binding to the integrin blocks the interaction with its endothelial receptor, the VCAM-1, leading to the inhibition of leukocyte migration into the CNS and attenuating inflammation                                                                                                                                                                                           [@b5-tcrm-14-1765], [@b20-tcrm-14-1765]
  Teriflunomide           Aubagio^®^; Sanofi, Paris, France                                                   Teriflunomide has anti-inflammatory properties that reversibly inhibits the mitochondrial enzyme DHO-DH, required for the pyrimidine synthesis. The result is that teriflunomide reduces the proliferation of dividing cells that need the synthesis of pyrimidine. In this way, teriflunomide reduces the proliferation of T and B cells                                                                                                                                                                 [@b7-tcrm-14-1765], [@b22-tcrm-14-1765]
  FTY720                  Gilenya^®^; Novartis, Basel, Switzerland                                            FTY720 is a S1P receptor modulator. After the action of sphingosine kinase, the active metabolite FTY720 phosphate binds to S1P receptor 1 located on lymphocytes and crosses the blood--brain barrier to bind to S1P receptor 1 located on neural cells in the CNS. Acting as an antagonist of S1P receptors on lymphocytes, FTY720 phosphate inhibits the exit of lymphocytes from lymph nodes, causing a redistribution. It reduces the infiltration of lymphocytes into the CNS                       [@b8-tcrm-14-1765], [@b21-tcrm-14-1765]
  DMF                     Tecfidera^®^; Biogen, Cambridge, MA, USA                                            DMF exerts a cytoprotective effect on neuronal cells by activating the Nrf2                                                                                                                                                                                                                                                                                                                                                                                                                               [@b9-tcrm-14-1765], [@b23-tcrm-14-1765]

**Abbreviations:** CNS, central nervous system; DHO-DH, dihydroorotate dehydrogenase; DMF, dimethyl fumarate; FTY720, fingolimod; GA, glatiramer acetate; IFN, interferon; IFN β-1a-A, interferon β-1a Avonex^®^; IFN β-1a-R, interferon β-1a Rebif^®^; IFN β-1b-B, interferon β-1b Betaferon^®^; IFN β-1b-E, interferon β-1b Extavia^®^; NAT, natalizumab; Nrf2, nuclear factor erythroid 2-related factor 2; PEG IFN β-1a, peginterferon β-1a; S1P, sphingosine 1-phosphate; VCAM-1, vascular cell adhesion molecule-1.

###### 

Clinical data of RR-MS patients and adverse event characteristics for all the reported expected reactions

  Drug            Medical history of the patient                             Characteristics of the adverse event                                                                                                                
  --------------- ---------------------------------------------------------- ----------------------------------------------------------------------------------------- ------- -------------------------------------- ---------- ---------------------------
  IFN β-1a-A      No                                                         No                                                                                        192     Myalgia                                Mild       Continuation
                                                                                                                                                                               Arthralgia                             Mild       
                  No                                                         Steroids                                                                                  384     Flu-like symptoms                      Mild       Continuation
                                                                                                                                                                               Mixed anxiety-depressive disorder      Mild       
                  Hashimoto thyroiditis                                      No                                                                                        180     Leukopenia                             Severe     Discontinuation
                  No                                                         No                                                                                        104     Nephrotic syndrome                     Severe     Discontinuation
                  No                                                         No                                                                                        104     Flu-like symptoms                      Mild       Continuation
                                                                                                                                                                               Pruritus                               Mild       
                  Dyslipidemia, anxiety                                      Methylprednisolone                                                                        308     Injection site necrosis                Severe     Temporary
                                                                                                                                                                               Diarrhea                               Severe     discontinuation
                  No                                                         No                                                                                        886     Flu-like symptoms                      Mild       Discontinuation
                  No                                                         No                                                                                        260     Pain                                   Mild       Continuation
                  Headache                                                   No                                                                                        17      Hepatic transaminases increased        Moderate   Discontinuation
                  Thyroiditis, headache, mitral insufficiency                No                                                                                        68      Flu-like symptoms                      Moderate   Discontinuation
                  Hypertension                                               No                                                                                        NA      Injection site bruising                Moderate   Continuation
                  No                                                         No                                                                                        NA      Flu-like symptoms                      Mild       Continuation
                  No                                                         No                                                                                        468     Flu-like symptoms                      Mild       Continuation
                  No                                                         No                                                                                        NA      Flu-like symptoms                      Mild       Continuation
                  No                                                         No                                                                                        52      Myalgia                                Mild       Continuation
                                                                                                                                                                               Arthralgia                             Mild       
                  Diabetes type 1                                            No                                                                                        1       Vomiting                               Mild       Continuation
                  No                                                         No                                                                                        52      Malaise                                Moderate   Discontinuation
                                                                                                                                                                               Tachycardia                            Moderate   
                  No                                                         No                                                                                        NA      Pyrexia                                Mild       Continuation
                  No                                                         No                                                                                        4       Pyrexia                                Mild       Continuation
                  Diabetes                                                   No                                                                                        104     Flu-like symptoms                      Mild       Continuation
                  No                                                         No                                                                                        NA      Flu-like symptoms                      Moderate   Continuation
                  No                                                         No                                                                                        52      Flu-like symptoms                      Mild       Discontinuation
  IFN β-1a-R      Hashimoto thyroiditis                                      Steroids, Cyclophosphamide, Dexamethasone, Methotrexate, IFN β-1a-R, Methylprednisolone   2,016   Urticaria                              Severe     Continuation
                  No                                                         IFN β-1a-A                                                                                2,000   Arthralgia                             Moderate   Discontinuation
                  Diabetes type 1, thyroiditis                               No                                                                                        234     Flu-like symptoms                      Moderate   Continuation
                  Osteoporosis                                               No                                                                                        90      Flu-like symptoms                      Mild       Continuation
                  No                                                         Azathioprine                                                                              1,407   Injection site abscess                 Moderate   Continuation
                  No                                                         No                                                                                        NA      Insomnia                               Mild       Continuation
                  No                                                         No                                                                                        780     Musculoskeletal stiffness              Moderate   Discontinuation
                  Diabetes type 2, thyroiditis                               IFN β-1b-B                                                                                312     Flu-like symptoms                      Moderate   Discontinuation
                  Depression                                                 No                                                                                        NA      Headache                               Moderate   Discontinuation
                  No                                                         No                                                                                        312     Pyrexia                                Moderate   Continuation
                  No                                                         No                                                                                        36      Injection site pain                    Moderate   Continuation
                  No                                                         No                                                                                        NA      Flu-like symptoms                      Moderate   Continuation
                  No                                                         No                                                                                        12      Pain in extremity                      Mild       Continuation
                  Asthma                                                     No                                                                                        24      Flu-like symptoms                      Moderate   Discontinuation
                  No                                                         No                                                                                        1,251   Hepatic transaminases increased        Moderate   Continuation
                  Diabetes                                                   No                                                                                        468     Hepatic transaminases increased        Moderate   Continuation
                  No                                                         No                                                                                        2,190   Hepatic transaminases increased        Moderate   Continuation
                  No                                                         No                                                                                        75      Flu-like symptoms                      Mild       Continuation
                                                                                                                                                                               Insomnia                               Mild       
                  Hashimoto thyroiditis                                      No                                                                                        312     Injection site redness                 Mild       Continuation
                  Glaucoma                                                   No                                                                                        936     Headache                               Moderate   Continuation
                  Neurofibromatosis type 1                                   No                                                                                        36      Injection site necrosis                Moderate   Continuation
                                                                                                                                                                               Flu-like symptoms                      Moderate   
                  Hashimoto thyroiditis                                      No                                                                                        780     Headache                               Mild       Continuation
                  No                                                         GA, NAT                                                                                   468     Headache                               Moderate   Discontinuation
                                                                                                                                                                               Asthenia                               Moderate   
                  No                                                         No                                                                                        NA      Headache                               Moderate   Discontinuation
                                                                                                                                                                               Asthenia                               Moderate   
                  Raynaud syndrome                                           No                                                                                        NA      Headache                               Moderate   Continuation
                  Hashimoto thyroiditis                                      No                                                                                        NA      Headache                               Mild       Continuation
                  Diabetes type 1, thyroiditis                               No                                                                                        390     Flu-like symptoms                      Moderate   Discontinuation
                  No                                                         No                                                                                        468     Injection site erythema                Moderate   Continuation
  IFN β-1b-B      No                                                         IFN β-1a-A                                                                                1,900   Headache                               Mild       Discontinuation
                  No                                                         No                                                                                        1,800   Pyrexia                                Mild       Discontinuation
                                                                                                                                                                               Injection site pain                    Mild       
                  Bipolar disorder                                           GA, NAT, methylprednisolone                                                               667     Injection site abscess                 Severe     Discontinuation
                  Depression                                                 No                                                                                        NA      Headache                               Moderate   Discontinuation
                                                                                                                                                                               Paresthesia                            Moderate   
                  No                                                         No                                                                                        1,460   Injection site mass                    Mild       Discontinuation
                  No                                                         Cyclophosphamide                                                                          547     Gamma-glutamyl-transferase increased   Moderate   Discontinuation
                  No                                                         No                                                                                        912     Asthenia                               Moderate   Discontinuation
                                                                                                                                                                               Myasthenia                             Moderate   
                  No                                                         IFN β-1a-A                                                                                150     Pyrexia                                Moderate   Continuation
                                                                                                                                                                               Injection site pain                    Moderate   
                  Methylprednisolone and ketoprofen allergies                No                                                                                        912     Malaise                                Moderate   Continuation
                                                                                                                                                                               Injection site pain                    Moderate   
                  Vertigo                                                    No                                                                                        273     Injection site pain                    Moderate   Discontinuation
                  No                                                         No                                                                                        273     Injection site mass                    Moderate   Continuation
                  No                                                         No                                                                                        912     Injection site skin reaction           Moderate   Discontinuation
                  No                                                         No                                                                                        730     Injection site bruising                Moderate   Discontinuation
                                                                                                                                                                               Injection site pain                    Moderate   
                  Hypertension                                               No                                                                                        NA      Flu-like symptoms                      Mild       Continuation
                  Thyroiditis                                                IFN β-1a-A                                                                                105     Lymphopenia                            Moderate   Discontinuation
  IFN β-1b-E      No                                                         IFN β-1a-A, IFN β-1a-R, GA                                                                140     Abdominal pain                         Moderate   Discontinuation
                  Depression, disk herniation                                No                                                                                        135     Urticaria                              Mild       Continuation
  PEG IFN β-1a    No                                                         Methylprednisolone                                                                        6       Flu-like symptoms                      Severe     Continuation
                  Dysthyroidism, hypertension                                IFN β-1b-E, DMF, teriflunomide                                                            10      Injection site rash                    Mild       Discontinuation
                  No                                                         NA                                                                                        8       Flu-like symptoms                      Mild       Continuation
                  No                                                         NA                                                                                        NA      Flu-like symptoms                      NA         NA
                  Anemia                                                     IFN β-1a-A                                                                                NA      Lymphopenia                            Mild       Discontinuation
                  No                                                         NA                                                                                        12      Lymphopenia                            Mild       Discontinuation
                  No                                                         DMF                                                                                       2       Urticaria                              Moderate   Discontinuation
                  Depression                                                 IFN β-1a-R, IFN β-1a-A                                                                    3       Injection site redness                 Mild       Discontinuation
                  Diabetes                                                   IFN β-1a-A                                                                                2       Flu-like symptoms                      Moderate   Continuation
                                                                                                                                                                               Injection site redness                 Moderate   
                  Cardiopathy, capitellum fracture, duodeal ulcer, anxiety   IFN β-1b-B                                                                                2       Flu-like symptoms                      Moderate   Continuation
                                                                                                                                                                               Injection site redness                 Moderate   
                  Allergies                                                  IFN β-1a-R                                                                                2       Flu-like symptoms                      Moderate   Continuation
                                                                                                                                                                               Injection site rash                    Moderate   
                  No                                                         IFN β-1b-B                                                                                2       Flu-like symptoms                      Moderate   Continuation
                  Meningioma                                                 IFN β-1b-B, Teriflunomide                                                                 4       Myalgia                                Mild       Continuation
                                                                                                                                                                               Arthralgia                             Mild       
                  Depression                                                 IFN β-1b-B                                                                                4       Flu-like symptoms                      Moderate   Continuation
                                                                                                                                                                               Injection site redness                 Moderate   
                  No                                                         IFN β-1b-B                                                                                1       Arthralgia                             Moderate   Continuation
                  No                                                         IFN β-1a-A, IFN β-1a-R, mitoxantrone, GA, IFN β-1b-B, DMF                                 6       Lymphopenia                            Severe     Discontinuation
                  No                                                         IFN β-1a-A, IFN β-1a-R                                                                    1       Flu-like symptoms                      Moderate   Continuation
                                                                                                                                                                               Injection site rash                    Moderate   
                  Pulmonary valve stenosis                                   IFN β-1a-R                                                                                2       Pyrexia                                Moderate   Continuation
                                                                                                                                                                               Injection site rash                    Moderate   
                  No                                                         IFN β-1a-A                                                                                1       Injection site redness                 Moderate   Continuation
                  No                                                         No                                                                                        2       Injection site erythema                Moderate   Discontinuation
                  Glucose-6-phosphate dehydrogenase deficiency               GA                                                                                        4       Myalgia                                Moderate   Continuation
                                                                                                                                                                               Asthenia                               Moderate   
                  No                                                         IFN β-1b-B, teriflunomide                                                                 4       Myalgia                                Mild       Continuation
                                                                                                                                                                               Arthralgia                             Mild       
                  No                                                         No                                                                                        6       Thrombocytopenia                       Moderate   Discontinuation
                  Thyroiditis                                                Mitoxantrone, IFN β-1a-R                                                                  10      Flu-like symptoms                      Moderate   Continuation
                  No                                                         IFN β-1b-B                                                                                1       Injection site redness                 Mild       Continuation
                  No                                                         IFN β-1a-A                                                                                6       Flu-like symptoms                      Mild       Discontinuation
                  Thyroiditis                                                IFN β-1a-A                                                                                NA      Injection site erythema                Mild       Continuation
                  Diabetes                                                   No                                                                                        6       Flu-like symptoms                      Moderate   Continuation
                  Thyroiditis                                                IFN β-1a-A                                                                                6       Myalgia                                Mild       Discontinuation
                                                                                                                                                                               Urticaria                              Mild       
                  No                                                         IFN β-1a-R                                                                                NA      Pyrexia                                Mild       Continuation
                                                                                                                                                                               Injection site redness                 Mild       
                  No                                                         IFN β-1a-R, GA                                                                            10      Urticaria                              Moderate   Discontinuation
                  Anxiety                                                    IFN β-1a-A, IFN β-1b-B                                                                    NA      Flu-like symptoms                      Mild       Continuation
                  Anxiety                                                    IFN β-1b-B                                                                                1       Pyrexia                                Moderate   Continuation
                                                                                                                                                                               Injection site necrosis                Moderate   
                  No                                                         Azathioprine, IFN β-1a-R                                                                  1       Flu-like symptoms                      Mild       Continuation
                  No                                                         IFN β-1a-R                                                                                26      Pyrexia                                Mild       Continuation
                  No                                                         No                                                                                        6       Flu-like symptoms                      Mild       Continuation
                  No                                                         IFN β-1a-R, mitoxantrone, IFN β-1b-B, IFN β-1a-A                                          6       Flu-like symptoms                      Moderate   Continuation
                  No                                                         IFN β-1a-R                                                                                NA      Injection site redness                 Moderate   Continuation
                  No                                                         No                                                                                        NA      Flu-like symptoms                      Moderate   Continuation
                                                                                                                                                                               Hepatic transaminases increased        Moderate   
                  No                                                         No                                                                                        8       Pyrexia                                Moderate   Continuation
                  No                                                         IFN β-1b-B                                                                                NA      Asthenia                               Mild       Continuation
                                                                                                                                                                               Injection site redness                 Mild       
                  No                                                         No                                                                                        1       Pyrexia                                Mild       Continuation
                                                                                                                                                                               Injection site rash                    Mild       
  GA              Hypercholesterolemia, anxiety                              No                                                                                        620     Mixed anxiety-depressive disorder      Moderate   Discontinuation
                  No                                                         Methylprednisolone                                                                        48      Rash                                   Moderate   Discontinuation
                                                                                                                                                                               Tachycardia                            Moderate   
                                                                                                                                                                               Depression                             Moderate   
                  Allergic asthma                                            No                                                                                        2,002   Dyspnea                                Severe     Continuation
                                                                                                                                                                               Tachycardia                            Severe     
                                                                                                                                                                               Vomiting                               Severe     
                  Hiatal hernia, contact dermatitis                          Methylprednisolone, IFN β-1b-E, DMF                                                       60      Injection site rash                    Moderate   Continuation
                  Hypercholesterolemia                                       Methylprednisolone                                                                        140     Rash                                   Severe     Discontinuation
                                                                                                                                                                               Flushing                               Severe     
                                                                                                                                                                               Choking sensation                      Severe     
                  Anxiety                                                    IFN β-1b-B, NAT, DMF, teriflunomide                                                       90      Chest pain                             Moderate   Discontinuation
                                                                                                                                                                               Flushing                               Moderate   
                                                                                                                                                                               Syncope                                Moderate   
                  Gastroesophageal reflux disease, depression                No                                                                                        51      Injection site rash                    Mild       Continuation
                  Anxiety                                                    IFN β-1b-B                                                                                93      Choking sensation                      Severe     Discontinuation
                                                                                                                                                                               Hypersensitivity                       Severe     
                  No                                                         IFN β-1b-B, NAT                                                                           NA      Urticaria                              Moderate   Discontinuation
                  No                                                         IFN β-1a-A                                                                                NA      Urticaria                              Moderate   Discontinuation
                                                                                                                                                                               Tachycardia                            Moderate   
                                                                                                                                                                               Anxiety                                Moderate   
                  No                                                         IFN β-1a-R                                                                                NA      Injection site mass                    Mild       Continuation
                  No                                                         IFN β-1a-A                                                                                NA      Injection site pruritus                Mild       Continuation
                  No                                                         No                                                                                        NA      Injection site pain                    Moderate   Continuation
                                                                                                                                                                               Injection site mass                    Moderate   
                                                                                                                                                                               Dyspnea                                Moderate   
                                                                                                                                                                               Influenza                              Moderate   
                                                                                                                                                                               Palpitation                            Moderate   
                  No                                                         No                                                                                        NA      Injection site redness                 Moderate   Continuation
                                                                                                                                                                               Injection site mass                    Moderate   
                  No                                                         No                                                                                        1,567   Skin disorder                          Moderate   Discontinuation
                  Pituitary microadenoma                                     IFN β-1a-A                                                                                6       Injection site rash                    Moderate   Discontinuation
                  No                                                         IFN β-1a-A, IFN β-1a-R, IFN β-1b-B                                                        36      Influenza                              Moderate   Discontinuation
                  Thyroiditis                                                IFN β-1a-R                                                                                238     Injection site mass                    Mild       Continuation
                  Pneumonia with autoimmune features                         DMF, PEG IFN β-1a                                                                         16      Rash                                   Moderate   Discontinuation
                  No                                                         No                                                                                        67      Injection site mass                    Moderate   Continuation
                  No                                                         IFN β-1a-A                                                                                1       Anxiety                                Moderate   Continuation
                                                                                                                                                                               Vomiting                               Moderate   
                                                                                                                                                                               Visual field defect                    Moderate   
                                                                                                                                                                               Dyspnea                                Moderate   
                                                                                                                                                                               Confusional state                      Moderate   
                  No                                                         Azathioprine, IFN β-1a-A, IFN β-1a-R                                                      628     Pyrexia                                Moderate   Discontinuation
                                                                                                                                                                               Nausea                                 Moderate   
                                                                                                                                                                               Chest pain                             Moderate   
                  Myoclonic epilepsy                                         IFN β-1a-R                                                                                63      Hypersensitivity                       Moderate   Discontinuation
                  Depression, diabetes type 2, glaucoma                      No                                                                                        160     Rash                                   Moderate   Discontinuation
                                                                                                                                                                               Dyspnea                                Moderate   
                  No                                                         IFN β-1b-B                                                                                2       Pyrexia                                Moderate   Discontinuation
                                                                                                                                                                               Rash                                   Moderate   
                                                                                                                                                                               Motor dysfunction                      Moderate   
                  Thyroiditis                                                No                                                                                        238     Hypersensitivity                       Moderate   Discontinuation
  NAT             No                                                         No                                                                                        52      Pyrexia                                Mild       Continuation
                  No                                                         IFN β-1b-B, GA, IFN β-1a-A                                                                104     Pyrexia                                Mild       Continuation
                  No                                                         NA                                                                                        3       Pyrexia                                Moderate   Discontinuation
                                                                                                                                                                               Chest pain                             Moderate   
  FTY720          Bronchial asthma, allergies                                Methylprednisolone, IFN β-1a-A, GA, IFN β-1b-B                                            1,095   Headache                               Moderate   Discontinuation
                                                                                                                                                                               Pruritus                               Moderate   
                                                                                                                                                                               Urinary tract infection                Moderate   
                  Hypercholesterolemia                                       Methylprednisolone, cyclophosphamide, azathioprine                                        240     Hepatic enzyme increased               Severe     Temporary
                                                                                                                                                                               Influenza                              Severe     discontinuation
                                                                                                                                                                               Headache                               Severe     
                                                                                                                                                                               Peripheral edema                       Severe     
                  Neurogenic bladder                                         Methylprednisolone, azathioprine, IFN β-1b-E, IFN β-1a-A                                  730     Alopecia                               Moderate   Discontinuation
                  Diabetes type 1, thyroiditis                               Steroids, IFN β-1a-R, Methylprednisolone, NAT                                             120     Asthenia                               Moderate   Continuation
                  No                                                         No                                                                                        75      Headache                               Mild       Continuation
                  No                                                         GA                                                                                        270     Hepatic enzyme increased               Mild       NA
                  No                                                         IFN β-1a-A                                                                                120     Hepatic enzyme increased               Moderate   Temporary discontinuation
                  Hashimoto thyroiditis                                      GA, Azathioprine                                                                          547     Lymphopenia                            Moderate   Continuation
                  Panic attacks, hyperandrogenism, retinal detachment        No                                                                                        1,460   Candidiasis                            Moderate   Continuation
                  No                                                         GA                                                                                        365     Leukopenia                             Severe     Temporary discontinuation
                  No                                                         IFN β-1b-B                                                                                365     Hepatic enzyme increased               Moderate   Discontinuation
                  No                                                         IFN β-1a-R, NAT, IFN β-1b-B                                                               455     Basal cell carcinoma                   Moderate   Discontinuation
  Teriflunomide   Autoimmune thyroiditis                                     IFN β-1a-A, IFN β-1a-R                                                                    510     Musculoskeletal pain                   Mild       Continuation
                  No                                                         Steroids                                                                                  970     Alopecia                               Mild       Continuation
                                                                                                                                                                               Respiratory tract infection            Mild       
                  Neurogenic bladder, gastroduodenal ulcer                   Aminopyridine, IFN β-1a-A, methylprednisolone                                             365     Asthenia                               Severe     Continuation
                                                                                                                                                                               Arthralgia                             Severe     
                                                                                                                                                                               Alopecia                               Severe     
                  Aniridia                                                   DMF                                                                                       NA      Hepatic transaminases increased        Mild       Continuation
                  No                                                         IFN β-1a-R                                                                                89      Leukopenia                             Mild       Continuation
                  Mixed anxiety-depressive disorder                          IFN β-1a-A                                                                                540     Hypertension                           Moderate   Temporary discontinuation
                  No                                                         No                                                                                        35      Hepatic transaminases increased        Mild       Continuation
                  Ebstein anomaly                                            IFN β-1a-A, IFN β-1b-B, IFN β-1a-R, NAT                                                   30      Musculoskeletal pain                   Moderate   Discontinuation
                  Osgood--Schlatter disease                                  IFN β-1a-R                                                                                7       Hypertension                           Moderate   Discontinuation
                  Panic attacks                                              GA                                                                                        10      Gastroenteritis                        Moderate   Discontinuation
                                                                                                                                                                               Headache                               Moderate   
                                                                                                                                                                               Pain                                   Moderate   
                  Panic attacks, thyroiditis                                 IFN β-1a-A, IFN β-1a-R                                                                    7       Abdominal pain upper                   Moderate   Continuation
                                                                                                                                                                               Nausea                                 Moderate   
                  Asthma, gastroesophageal reflux disease                    Azathioprine, IFN β-1a-A, mitoxantrone, GA, immunoglobulins, IFN β-1b-B, NAT, FTY720      365     Alopecia                               Moderate   Discontinuation
                                                                                                                                                                               Diarrhea                               Moderate   
                  Depression, neonatal asphyxia, intellectual disability     IFN β-1a-A                                                                                30      Diarrhea                               Mild       Continuation
                  Autoimmune thyroiditis                                     IFN β-1a-R, GA, azathioprine                                                              30      Alopecia                               Moderate   Discontinuation
                                                                                                                                                                               Diarrhea                               Moderate   
                                                                                                                                                                               Weight decrease                        Moderate   
                  No                                                         IFN β-1a-A, IFN β-1a-R                                                                    90      Alopecia                               Moderate   Continuation
                  No                                                         IFN β-1a-R, mitoxantrone, IFN β-1b-E                                                      547     Hypertension                           Moderate   Temporary discontinuation
                  Disk herniation                                            No                                                                                        60      Hypertension                           Moderate   Continuation
                  Anxiety, pain in extremity                                 GA                                                                                        NA      Gastroenteritis                        Moderate   Continuation
                                                                                                                                                                               Headache                               Moderate   
                                                                                                                                                                               Pain                                   Moderate   
                  Gastroesophageal reflux disease                            GA, IFN β-1b-B                                                                            182     Hepatic transaminases increased        Severe     Discontinuation
                  Autoimmune thyroiditis                                     Azathioprine, IFN β-1a-R                                                                  90      Hypertension                           Moderate   Continuation
                  No                                                         IFN β-1b-B                                                                                16      Rash                                   Moderate   Discontinuation
                  Diabetes type 2, thyroiditis                               IFN β-1a-A                                                                                365     Gastroenteritis                        Moderate   Discontinuation
                  No                                                         IFN β-1a-R, IFN β-1a-A                                                                    60      Hypertension                           Moderate   Discontinuation
                  No                                                         IFN β-1a-R, mitoxantrone, GA                                                              60      Alopecia                               Mild       Continuation
                  No                                                         IFN β-1a-R, GA                                                                            60      Pancreatitis                           Moderate   Temporary discontinuation
                  Depression                                                 IFN β-1b-B                                                                                730     Hypertension                           Moderate   Continuation
                  No                                                         IFN β-1a-A, IFN β-1a-R, GA, azathioprine                                                  90      Neutropenia                            Moderate   Discontinuation
                  No                                                         IFN β-1a-R                                                                                365     Diarrhea                               Mild       Continuation
                  Autoimmune thyroiditis                                     IFN β-1a-R                                                                                365     Alopecia                               Moderate   Continuation
                                                                                                                                                                               Diarrhea                               Moderate   
                  No                                                         IFN β-1a-A                                                                                365     Alopecia                               Mild       Continuation
                                                                                                                                                                               Pancreatitis                           Mild       
                  No                                                         IFN β-1a-A, IFN β-1a-R                                                                    240     Alopecia                               Mild       Continuation
                  Autoimmune thyroiditis                                     IFN β-1a-A, GA                                                                            30      Abdominal pain upper                   Mild       Continuation
                  Panic attacks, thyroiditis                                 IFN β-1a-A, IFN β-1a-R                                                                    547     Nausea                                 Moderate   Discontinuation
                                                                                                                                                                               Abdominal pain upper                   Moderate   
                                                                                                                                                                               Diarrhea                               Moderate   
                  No                                                         IFN β-1a-A, IFN β-1a-R                                                                    NA      Diarrhea                               Mild       Continuation
                  No                                                         IFN β-1a-A, IFN β-1a-R, GA, DMF                                                           NA      Abdominal pain upper                   Moderate   Discontinuation
                                                                                                                                                                               Diarrhea                               Moderate   
                                                                                                                                                                               Hepatic transaminases increased        Moderate   
                  No                                                         No                                                                                        912     Abdominal pain upper                   Mild       Discontinuation
                                                                                                                                                                               Nausea                                 Mild       
  DMF             No                                                         Steroids, IFN β-1a-A, IFN β-1a-R, GA                                                      410     Abdominal pain upper                   Mild       Continuation
                                                                                                                                                                               Flushing                               Mild       
                                                                                                                                                                               Pruritus                               Mild       
                  No                                                         GA, IFN β-1a-A, teriflunomide                                                             210     Abdominal pain upper                   Mild       Continuation
                                                                                                                                                                               Flushing                               Mild       
                                                                                                                                                                               Burning sensation                      Mild       
                  No                                                         Steroids                                                                                  720     Flushing                               Moderate   Temporary
                                                                                                                                                                               Pruritus                               Moderate   discontinuation
                                                                                                                                                                               Hepatic transaminases increased        Moderate   
                  No                                                         Methylprednisolone, IFN β-1a-A, IFN β-1a-R                                                900     Flushing                               Mild       Continuation
                                                                                                                                                                               Rash                                   Mild       
                  No                                                         No                                                                                        25      Abdominal pain                         Moderate   Discontinuation
                                                                                                                                                                               Diarrhea                               Moderate   
                  No                                                         IFN β-1b-B, methotrexate                                                                  450     Gastrointestinal disorder              Mild       Continuation
                  Neurogenic bladder                                         IFN β-1a-R                                                                                180     Rash                                   Severe     Discontinuation
                  Myastenia, meningioma                                      IFN β-1a-R, GA                                                                            300     Lymphopenia                            Moderate   Temporary discontinuation
                  No                                                         No                                                                                        420     Drug-induced liver injury              Severe     Discontinuation
                  Anxiety                                                    IFN β-1a-R                                                                                180     Diarrhea                               Severe     Discontinuation
                                                                                                                                                                               Abdominal pain                         Severe     
                  No                                                         No                                                                                        30      Abdominal pain                         Moderate   Discontinuation
                  No                                                         IFN β-1b-B, IFN β-1a-A                                                                    30      Gastrointestinal disorder              Mild       Continuation
                  Hashimoto thyroiditis                                      IFN β-1a-R                                                                                14      Flushing                               Mild       Continuation
                  No                                                         FTY720                                                                                    2       Abdominal pain                         Moderate   Discontinuation
                                                                                                                                                                               Flushing                               Moderate   
                  Diabetes type 2, thyroiditis                               IFN β-1b-B                                                                                180     Abdominal pain                         Moderate   Discontinuation
                                                                                                                                                                               Flushing                               Moderate   
                  Headache, primary fibromyalgia                             IFN β-1a-R, GA                                                                            60      Asthenia                               Moderate   Discontinuation
                  No                                                         No                                                                                        NA      Pruritus                               Mild       Continuation
                                                                                                                                                                               Flushing                               Mild       
                  No                                                         IFN β-1a-R                                                                                40      Rash                                   Moderate   Continuation
                  No                                                         No                                                                                        960     Flushing                               Moderate   Continuation
                  Panic attacks, claustrophobia, thyroiditis                 IFN β-1a-A, IFN β-1b-B, NAT                                                               NA      Rash                                   Moderate   Discontinuation
                  No                                                         GA                                                                                        1,094   Flushing                               Moderate   Continuation
                  Depression                                                 IFN β-1a-A, NAT                                                                           60      Pruritus                               Moderate   Discontinuation
                  No                                                         IFN β-1a-R, GA                                                                            365     Flushing                               Moderate   Continuation
                                                                                                                                                                               Nausea                                 Moderate   
                  Autoimmune thyroiditis                                     IFN β-1a-A                                                                                30      Gastroenteritis                        Severe     Discontinuation
                  No                                                         IFN β-1a-A                                                                                NA      Flushing                               Mild       Continuation
                                                                                                                                                                               Diarrhea                               Mild       
                  Hypertension, epilepsy                                     IFN β-1a-R                                                                                30      Diarrhea                               Severe     Discontinuation
                  No                                                         No                                                                                        NA      Abdominal pain upper                   Moderate   Continuation
                                                                                                                                                                               Flushing                               Moderate   
                  Autoimmune thyroiditis                                     IFN β-1b-B                                                                                730     Abdominal pain upper                   Mild       Continuation
                  No                                                         IFN β-1b-B                                                                                60      Gastrointestinal disorder              Moderate   Discontinuation
                  Multinodular goiter                                        IFN β-1a-R                                                                                NA      Flushing                               Mild       Continuation
                                                                                                                                                                               Gastrointestinal disorder              Mild       
                  Autoimmune thyroiditis                                     IFN β-1b-E                                                                                NA      Flushing                               Mild       Continuation
                  Hepatitis B                                                IFN β-1a-A, NAT                                                                           NA      Flushing                               Moderate   Continuation
                  Hashimoto thyroiditis, psoriasis                           IFN β-1b-B, GA                                                                            60      Gastrointestinal disorder              Moderate   Discontinuation
                  No                                                         IFN β-1b-B                                                                                900     Flushing                               Mild       Continuation
                  No                                                         IFN β-1a-R                                                                                240     Flushing                               Moderate   Continuation
                                                                                                                                                                               Pruritus                               Moderate   
                  Psoriasis                                                  No                                                                                        730     Flushing                               Moderate   Continuation
                  No                                                         GA                                                                                        60      Gastrointestinal disorder              Mild       Discontinuation
                  No                                                         No                                                                                        420     Flushing                               Mild       Continuation
                                                                                                                                                                               Diarrhea                               Mild       
                  No                                                         IFN β-1a-A, IFN β-1b-B, mitoxantrone, GA                                                  60      Flushing                               Mild       Continuation
                  No                                                         IFN β-1a-R                                                                                NA      Flushing                               Mild       Continuation
                                                                                                                                                                               Abdominal pain                         Mild       
                  No                                                         IFN β-1b-B                                                                                730     Flushing                               Mild       Continuation
                  Hashimoto thyroiditis                                      IFN β-1b-B                                                                                120     Flushing                               Mild       Continuation
                                                                                                                                                                               Abdominal pain                         Mild       
                  Anxiety, depression                                        IFN β-1b-B, IFN β-1a-R, GA, teriflunomide                                                 240     Hepatic transaminases increased        Moderate   Discontinuation
                  No                                                         IFN β-1a-A                                                                                180     Flushing                               Mild       Continuation
                  Thyroiditis                                                IFN β-1b-B, FTY720                                                                        300     Flushing                               Moderate   Discontinuation
                                                                                                                                                                               Lymphopenia                            Moderate   
                  Hypertension                                               No                                                                                        180     Flushing                               Mild       Continuation
                  No                                                         GA, IFN β-1a-R                                                                            60      Flushing                               Mild       Continuation
                                                                                                                                                                               Gastrointestinal disorder              Mild       
                  Hypertension                                               No                                                                                        60      Flushing                               Mild       Continuation
                  No                                                         IFN β-1a-A                                                                                480     Lymphopenia                            Moderate   Discontinuation
                  No                                                         IFN β-1a-R                                                                                240     Flushing                               Moderate   Continuation
                                                                                                                                                                               Pruritus                               Moderate   
                  No                                                         IFN β-1b-B                                                                                NA      Flushing                               Mild       Continuation
                  No                                                         IFN β-1a-A                                                                                60      Nausea                                 Moderate   Discontinuation
                                                                                                                                                                               Gastrointestinal disorder              Moderate   
                                                                                                                                                                               Abdominal pain                         Moderate   
                  No                                                         IFN β-1a-R                                                                                NA      Flushing                               Moderate   Continuation
                                                                                                                                                                               Diarrhea                               Moderate   
                  No                                                         No                                                                                        NA      Flushing                               Mild       Continuation

**Abbreviations:** DMF, dimethyl fumarate; FTY720, fingolimod; GA, glatiramer acetate; IFN β-1a-A, interferon β-1a Avonex^®^; IFN β-1a-R, interferon β-1a Rebif^®^; IFN β-1b-B, interferon β-1b Betaferon^®^; IFN β-1b-E, interferon β-1b Extavia^®^; NAT, natalizumab; PEG IFN β-1a, peginterferon β-1a; RR-MS, relapsing-remitting multiple sclerosis; NA, not available.

###### 

Clinical data of RR-MS patients and adverse event characteristics for all the reported unexpected reactions

  Drug                 Medical history of the patient                           Characteristics of the adverse event                                                                                                                   
  -------------------- -------------------------------------------------------- -------------------------------------------------------------------------------------- ------- -------------------------------------------- ---------- ---------------------------
  IFN β-1a-A           Dyslipidemia, anxiety                                    Methylprednisolone                                                                     308     Erectile dysfunction                         Severe     Temporary discontinuation
                       No                                                       No                                                                                     4       Irritable mood                               Moderate   Discontinuation
  IFN β-1a-R           Wolff-Parkinson-White syndrome                           No                                                                                     1,251   Erectile dysfunction                         Mild       Discontinuation
                       No                                                       No                                                                                     1,095   Panic attacks                                Moderate   Discontinuation
                                                                                                                                                                               Tachycardia                                  Moderate   
                       No                                                       No                                                                                     NA      Nervousness                                  Moderate   Discontinuation
  IFN β-1b-E           No                                                       IFN β-1a-A, IFN β-1a-R, GA                                                             140     Rachialgia                                   Moderate   Discontinuation
  Peginterferon β-1a   Dysthyroidism, hypertension                              IFN β-1b-E, DMF, Teriflunomide                                                         10      Unmotivated anger                            Mild       Discontinuation
                       No                                                       NA                                                                                     NA      Localized erythema                           NA         NA
                       No                                                       DMF                                                                                    2       Eyelid edema                                 Moderate   Discontinuation
                       No                                                       IFN β-1b-B                                                                             1       Abdominal pain                               Moderate   Continuation
                                                                                                                                                                               Diarrhea                                     Moderate   
                                                                                                                                                                               Confusional state                            Moderate   
                       No                                                       No                                                                                     1       Oral aphthae                                 Mild       Continuation
  GA                   No                                                       No                                                                                     2,555   Vertigo                                      Moderate   Continuation
                                                                                                                                                                               Postural instability                         Moderate   
                                                                                                                                                                               Right hemiparesis                            Mild       
                       Allergic asthma                                          No                                                                                     2,002   Tachypnea                                    Severe     Continuation
                       Anxiety                                                  No                                                                                     67      Panic attacks                                Moderate   Continuation
                       No                                                       IFN β-1a-A, IFN β-1a-R, IFN β-1b-B                                                     36      Panic attacks                                Moderate   Discontinuation
                       No                                                       IFN β-1a-A                                                                             1,099   Panic attacks                                Mild       Continuation
                       No                                                       IFN β-1a-R                                                                             940     Irritable mood                               Mild       Continuation
  NAT                  No                                                       GA                                                                                     36      Femoral fracture                             Severe     Discontinuation
                       Diabetes type 1                                          Methylprednisolone                                                                     29      Paresthesia                                  Mild       Continuation
                                                                                                                                                                               Hyposthenia                                  Mild       
                       Mixed anxiety-depressive disorder, conversion disorder   GA                                                                                     34      Bronchopneumonia                             Moderate   Continuation
                       No                                                       IFN β-1b-B, GA, IFN β-1a-A                                                             104     Cough                                        Mild       Continuation
                       No                                                       IFN β-1b-B                                                                             109     Diarrhea                                     Moderate   Continuation
                       No                                                       NA                                                                                     3       Cough                                        Moderate   Discontinuation
  Fingolimod           Depression                                               IFN β-1a-A, IFN β-1b-E                                                                 560     Aortic dissection leading to death           Severe     NA
                       No                                                       IFN β-1a-A                                                                             605     Warts                                        Severe     Discontinuation
                       Hypotyroidism                                            Cyclophosphamide, methotrexate, mitoxantrone                                           1,440   Insomnia                                     Severe     Continuation
                                                                                                                                                                               Behavioral disorder                          Severe     
                       Bronchial asthma, allergies                              Methylprednisolone, IFN β-1a-A, GA, IFN β-1b-B                                         1,095   Pain in extremity                            Moderate   Discontinuation
                                                                                                                                                                               Muscle spasms                                Moderate   
                       Neurogenic bladder                                       Methylprednisolone, azathioprine, IFN β-1b-E, IFN β-1a-A                               730     Pain in extremity                            Moderate   Discontinuation
                       Diabetes type 1, thyroiditis                             Steroids, IFN β-1a-R, methylprednisolone, NAT                                          120     Arthralgia                                   Moderate   Continuation
                                                                                                                                                                               Insomnia                                     Moderate   
                       Acne                                                     DMF                                                                                    52      Acne worsening                               Moderate   Continuation
                       Cervical spine trauma                                    No                                                                                     70      Chest pain                                   Moderate   Continuation
                       No                                                       No                                                                                     75      Anxiety                                      Mild       Continuation
                       No                                                       IFN β-1a-A, IFN β-1a-R                                                                 60      Hypotyroidism                                Moderate   Continuation
                       Depression                                               Azathioprine, IFN β-1a-R                                                               1,825   Bilateral ovarian carcinoma                  Severe     Discontinuation
  Teriflunomide        No                                                       No                                                                                     390     Depression                                   Moderate   Discontinuation
                       Neurogenic bladder, gastroduodenal ulcer                 Aminopyridine, IFN β-1a-A, methylprednisolone                                          365     Chest pain                                   Severe     Continuation
                                                                                                                                                                               Herpes zoster                                Severe     
                       Ebstein anomaly                                          IFN β-1a-A, IFN β-1b-B, IFN β-1a-R, NAT                                                30      Tachycardia                                  Moderate   Discontinuation
                       Asthma, gastroesophageal reflux disease                  Azathioprine, IFN β-1a-A, mitoxantrone, GA, immunoglobulins, IFN β-1b-B, NAT, FTY720   365     Pruritus                                     Moderate   Discontinuation
                       No                                                       IFN β-1a-R, mitoxantrone, IFN β-1b-E                                                   547     Tachycardia                                  Moderate   Temporary discontinuation
                       No                                                       IFN β-1a-A, IFN β-1a-R, NAT                                                            60      Progressive multifocal leukoencephalopathy   Severe     Discontinuation
  DMF                  No                                                       IFN β-1a-A, IFN β-1a-R                                                                 160     Thrombocytosis                               Mild       Continuation
                       No                                                       IFN β-1b-B, IFN β-1a-A                                                                 900     Insomnia                                     Mild       Continuation
                       Neurogenic bladder                                       IFN β-1a-R                                                                             180     Headache                                     Severe     Discontinuation
                       Petrous apex cholesterol granuloma                       IFN β-1a-R                                                                             300     Omphalitis                                   Moderate   Discontinuation
                       Headache, primary fibromyalgia                           IFN β-1a-R, GA                                                                         60      Pain                                         Moderate   Discontinuation
                       No                                                       No                                                                                     60      Headache                                     Moderate   Discontinuation
                                                                                                                                                                               Respiratory failure                          Moderate   
                       No                                                       GA                                                                                     1,094   Vertigo                                      Moderate   Continuation
                                                                                                                                                                               Rhinitis                                     Moderate   
                       No                                                       IFN β-1a-R, GA                                                                         365     Dyspnea                                      Moderate   Continuation
                                                                                                                                                                               Vaginal discharge                            Moderate   
                       Autoimmune thyroiditis                                   IFN β-1a-A                                                                             30      Lymphadenopathy                              Severe     Discontinuation
                       Hepatitis B                                              IFN β-1a-A, NAT                                                                        NA      Weight decrease                              Moderate   Continuation
                                                                                                                                                                               Chest pain                                   Moderate   
                       No                                                       IFN β-1a-R                                                                             240     Vertigo                                      Moderate   Continuation

**Abbreviations:** DMF, dimethyl fumarate; GA, glatiramer acetate; IFN β-1a-A, interferon β-1a Avonex^®^; IFN β-1a-R, interferon β-1a Rebif^®^; IFN β-1b-B, interferon β-1b Betaferon^®^; IFN β-1b-E, interferon β-1b Extavia^®^; NAT, natalizumab; RR-MS, relapsing-remitting multiple sclerosis; NA, not available.
